Is a total prostate-specific antigen of 0.4 ng/mL, free PSA of 0.1 ng/mL, and free PSA percentage of 25% normal for a 37‑year‑old man, and what follow‑up is indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PSA Interpretation for a 37-Year-Old Male

These PSA values are completely normal for a 37-year-old man and require only routine follow-up with repeat PSA testing at age 40-45, with no immediate concern for prostate cancer.

Current Risk Assessment

Your patient's PSA values fall well within the expected normal range for his age group:

  • Total PSA of 0.4 ng/mL is significantly below all age-specific reference ranges, which for men aged 40-49 years range from 0-2.0 to 0-2.5 ng/mL depending on ethnicity 1
  • The median PSA for men in their 40s is 0.7 ng/mL, making this patient's value lower than the median 1
  • At PSA ≤0.5 ng/mL, the risk of prostate cancer is only 6.6%, with just 12.5% of those cancers being high-grade 1

Free PSA Percentage Interpretation

The free PSA percentage of 25% is reassuring in this clinical context:

  • Free PSA percentage becomes clinically relevant primarily when total PSA is elevated (4-10 ng/mL), not at these very low total PSA levels 1
  • At total PSA values of 0-2.5 ng/mL, the probability of cancer is approximately 1% regardless of free PSA percentage 2
  • A free PSA percentage of 25% is well above the concerning threshold of <10% that would suggest increased cancer risk in the diagnostic gray zone 1

Recommended Management Strategy

No diagnostic workup is indicated at this time. Follow this approach:

Immediate Actions

  • No prostate biopsy is warranted based on these values 1
  • Digital rectal examination (DRE) can be deferred until age 40 when baseline screening typically begins 1

Follow-Up Timeline

  • Repeat PSA testing at age 40 as part of baseline prostate cancer screening 1
  • If PSA remains <1.0 ng/mL at age 40, repeat at age 45 1
  • If PSA >1.0 ng/mL at age 40, initiate annual monitoring 1

PSA Velocity Monitoring (For Future Reference)

When this patient reaches screening age, PSA velocity will become relevant:

  • For men with PSA <4.0 ng/mL, a PSA velocity >0.35 ng/mL per year is concerning 1
  • Age-adjusted PSA velocity threshold for men ages 40-59 is 0.25 ng/mL per year 1
  • At least three PSA measurements over 18-24 months are required to reliably calculate PSA velocity 1

Important Caveats

Risk Factors That Would Modify This Approach

  • African-American ethnicity warrants earlier and more frequent screening starting at age 40 1
  • First-degree family history of prostate cancer (father, brother) indicates higher lifetime risk and earlier screening 1
  • These risk factors would justify annual PSA monitoring starting now rather than waiting until age 40 1

Factors That Can Affect PSA Levels

  • Ejaculation within 48 hours can elevate PSA; results are more reliable after 48 hours of abstinence 1
  • Prostate biopsy causes substantial PSA elevation; wait 3-6 weeks before testing 1
  • Laboratory variability can range 20-25%; use the same assay for longitudinal monitoring 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Low-Risk Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Is a total prostate-specific antigen of 1.0 ng/mL with free PSA 0.2 ng/mL (free‑PSA percentage 20%) normal for a 42‑year‑old man, and what follow‑up is indicated?
In a 69-year-old asymptomatic man with total prostate-specific antigen 0.6 ng/mL, free prostate-specific antigen 0.1 ng/mL (free PSA percentage 17%), what is the appropriate management?
What is the interpretation of a PSA-free PSA ratio and PSA density for a patient with a total PSA of 1.38, free PSA of 0.21, and prostate volume of 25ml, while taking dutasteride?
In a 40‑year‑old man with a family history of prostate cancer and a total prostate-specific antigen (PSA) of 0.8 ng/mL, free prostate-specific antigen (PSA) of 0.20 ng/mL (percent free prostate-specific antigen 25%), is this concerning and what is the appropriate plan of care?
What is the best course of action for an elderly man with a low Prostate-Specific Antigen (PSA) density of 0.1 and a negative Prostate Magnetic Resonance Imaging (MRI) result?
In a 47-year-old woman with diabetes who has hand swelling and xerosis, could the swelling be due solely to worsening xerosis rather than infection?
In an acute setting, for a 49‑year‑old patient with new‑onset vertigo and tachycardia, is aspirin an appropriate first‑line therapy when not in a hospital or doctor's office?
Is a tumor proportion score of 4% on a melanoma biopsy predictive of a specific treatment?
In a 68-year-old man with a 4‑week symmetric proximal weakness of the arms and legs, no pain or sensory loss, normal sensation, hyperreflexia, and no bladder or autonomic symptoms, what is the most likely diagnosis?
What are the distinguishing clinical features of vestibular neuritis versus labyrinthitis and the recommended management for each?
What is the recommended amoxicillin dosage for a severe odontogenic infection in an adult without penicillin allergy, and how should it be adjusted for impaired renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.